BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18802077)

  • 1. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development.
    Mori Y; Tsuji S; Inui M; Sakamoto Y; Endo S; Ito Y; Fujimura S; Koga T; Nakamura A; Takayanagi H; Itoi E; Takai T
    J Immunol; 2008 Oct; 181(7):4742-51. PubMed ID: 18802077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
    Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
    J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation.
    Chung DH; Humphrey MB; Nakamura MC; Ginzinger DG; Seaman WE; Daws MR
    J Immunol; 2003 Dec; 171(12):6541-8. PubMed ID: 14662855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function.
    Humphrey MB; Daws MR; Spusta SC; Niemi EC; Torchia JA; Lanier LL; Seaman WE; Nakamura MC
    J Bone Miner Res; 2006 Feb; 21(2):237-45. PubMed ID: 16418779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells.
    Tenca C; Merlo A; Merck E; Bates EE; Saverino D; Simone R; Zarcone D; Trinchieri G; Grossi CE; Ciccone E
    J Immunol; 2005 Jun; 174(11):6757-63. PubMed ID: 15905516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells.
    Yamada T; Yamazaki H; Yamane T; Yoshino M; Okuyama H; Tsuneto M; Kurino T; Hayashi S; Sakano S
    Blood; 2003 Mar; 101(6):2227-34. PubMed ID: 12411305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of the metalloproteinases ADAM10 or ADAM17 promotes osteoclast differentiation.
    Babendreyer A; Kieselhorst J; Rinkens C; Lyashenko AM; Düsterhöft S; Jahr H; Craveiro RB; Wolf M; Ludwig A
    Cell Commun Signal; 2024 Jun; 22(1):322. PubMed ID: 38863060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic insight into osteoclast differentiation in osteoimmunology.
    Takayanagi H
    J Mol Med (Berl); 2005 Mar; 83(3):170-9. PubMed ID: 15776286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.